Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will hold an earnings conference call on September 14, 2022, at 10:30 am Eastern Time, to discuss its first-quarter fiscal year 2023 results. The financial results will be released prior to the call, and management will answer pre-submitted questions from investors. Participants can join via the provided toll-free and toll dial-in numbers. The call will also be accessible online and available for replay on the company’s investor relations page.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reports successful results for its PolyTope® TATX-03 antibody therapy against COVID-19 variants, including the Omicron BA.5 subvariant. Validated by the Max von Pettenkofer Institute, the therapy showcases effectiveness in neutralizing various strains that challenge other commercial products. As the company approaches clinical trials, its Chief Scientific Officer emphasizes the therapy's potential and the urgency for effective COVID-19 treatments amidst evolving variants.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported record revenues of $19.4 million for the fiscal year ended April 30, 2022, an increase of 8.1% from $17.9 million in 2021. The quarterly revenue rose to $5.2 million, up 7.4% year-over-year. However, the company recorded a net loss of $16.7 million, widening from $7.3 million in the previous year. The increase in research and development expenditures also contributed to this loss. As of April 30, 2022, IPA's cash reserves decreased to $30 million from $41.8 million.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced it will host an earnings conference call on July 29, 2022, at 10:30 AM Eastern Time to discuss financial results and business highlights for Q4 and FY 2022. The call aims to engage investors during a Q&A session, with financial results released beforehand. Interested participants can join via toll-free and toll dial-in numbers, or listen live online. The event will be available for replay on the company's investor relations website.

ImmunoPrecise Antibodies Ltd. (IPA) announced positive results from its IND-enabling safety studies for the PolyTope® TATX-03 antibody cocktail aimed at COVID-19. Conducted under GLP standards, the studies revealed no adverse effects or off-target binding, supporting its safety and potential efficacy. No mortality or organ changes were observed during extensive testing, and cross-reactivity studies confirmed specificity to intended targets. These findings are crucial for clinical study approval, with first-in-human trials expected to begin later this year.

IPA subsidiary BioStrand secures €460,000 grant to enhance its LENSai platform by integrating HYFTs™ with 3D protein structures and functions. This funding, awarded by VLAIO, will support the platform's expansion to improve protein structure predictions, particularly for antibodies and GPCRs. BioStrand aims to provide a comprehensive AI Discovery platform, enhancing data analysis capabilities in biotechnology and precision medicine. Additionally, the company announces the immediate departure of Chief Business Officer Stefan Lang, effective immediately.

IPA announced encouraging results from its PolyTope® TATX-03 antibody cocktail, demonstrating effective neutralization against the Omicron sublineage BA.2. The data showed that the neutralization potency against BA.2 is comparable to BA.1.

All therapeutic antibodies in the cocktail maintained their reactivity to the BA.2 spike protein, reinforcing the product's consistency against SARS-CoV-2 variants.

Dr. Ilse Roodink emphasized the sustained efficacy of TATX-03 against evolving viral mutants, underlining its potential significance in combating COVID-19 variants.

ImmunoPrecise Antibodies has successfully completed its acquisition of BioStrand BV, BioKey BV, and BioClue BV, enhancing its capabilities in bioinformatics and biotechnology. This strategic move, valued at approximately €20 million, aims to leverage AI and machine learning technologies to innovate biotherapeutic discovery processes. The deal includes a combination of common shares and cash, as well as a potential earnout based on BioStrand's future profitability. The integration is expected to significantly improve personalized medicine development.

ImmunoPrecise Antibodies (IPA) has signed a share purchase agreement to acquire BioStrand, BioKey, and BioClue for a total of €20 million, with €2 million in cash and €18 million in equity. This acquisition enhances IPA's capabilities in bioinformatics and biotechnology through its proprietary HYFT patterns, which improve data analysis in multi-omics research. The transaction is expected to attract new clients and support IPA's Talem Therapeutics in antibody development. The deal received unanimous approval and is projected to close by April 15, 2022.